	US 11,701,412 B2
	Composition comprising highly-concentrated α1 proteinase inhibitor and method for obtaining thereof
James Rebbeor, Garner, NC (US); Charles Miller, Apex, NC (US); Anthony Klos, Raleigh, NC (US); Eric Allgaier, Wake Forest, NC (US); Thomas P. Zimmerman, Raleigh, NC (US); Kevin Wee, Wake Forest, NC (US); Michelle StPeter, Graner, NC (US); and Kelly Glancy, Holly Springs, NC (US)
Assigned to GRIFOLS WORLDWIDE OPERATIONS LIMITED, Dublin (IE)
Filed by GRIFOLS WORLDWIDE OPERATIONS LIMITED, Dublin (IE)
Filed on Sep. 22, 2021, as Appl. No. 17/448,509.
Application 17/448,509 is a continuation of application No. 16/529,686, filed on Aug. 1, 2019, granted, now 11,253,578.
Claims priority of provisional application 62/713,673, filed on Aug. 2, 2018.
Prior Publication US 2022/0000992 A1, Jan. 6, 2022
Int. Cl. A61K 38/55 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/30 (2006.01)

CPC A61K 38/55 (2013.01) [A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/30 (2013.01)]

13 Claims

1. A composition comprising Alpha1-Proteinase Inhibitor (A1PI) in an aqueous solution, wherein the concentration of A1PI is greater than 200 mg/ml, wherein the composition further comprises one or more uncharged excipient.